Shots:
- Accord Healthcare has launched Osvyrti & Jubereq, biosimilar versions of Amgen’s Prolia & Xgeva (denosumab), following patent expiry of reference products on Nov 27, 2025
- Osvyrti (60mg PFS) is indicated to treat osteoporosis in postmenopausal women & men at increased risk of fractures. It is also used to treat bone loss in pts on long-term glucocorticoids & prostate cancer pts on hormone ablation
- Jubereq (120mg vial) prevents SREs in adults with bone-involved malignancies & treats giant cell tumors of bone in adults & skeletally mature adolescents, where tumors are unresectable or can lead to severe morbidity upon resection
Ref: PRNewswire | Image: Accord Healthcare | Press Release
Related News: Accord Healthcare Reports the MHRA’s Approval of Hetronifly as 1L Treatment of ES-SCLC
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
